SREBF-1c SNPs and SREBF-2 SNPs predicted the 7-year incidence of NAFLD and diabetes and endothelial dysfunction markers at the end of follow-up in nonobese, nondiabetic, insulin-sensitive subjects without metabolic syndrome at baseline. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.